Polygenic Score (PGS) ID: PGS002257

Predicted Trait
Reported Trait Systolic blood pressure
Mapped Trait(s) systolic blood pressure (EFO_0006335)
Additional Trait Information Score is used in a combined blood pressure score by taking the average between GRS901_SBP and GRS901_DBP
Released in PGS Catalog: Feb. 16, 2022
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name GRS901_SBP
Development Method
Name Genome-wide significant variants
Parameters weighted GRSs for all pairwise-independent, LD-filtered (r2 < 0.1) previously reported variants and 535 genome-wide significant SNPs combined
Variants
Original Genome Build GRCh37
Number of Variants 884
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000283
Citation (link to publication) Evangelou E et al. Nat Genet (2018)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
757,601 individuals (100%)
PGS Evaluation
European: 60%
Not Reported: 10%
African: 10%
Multi-ancestry (including European): 10%
  • European
  • Not Reported
South Asian: 10%
10 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST006628
Europe PMC: 30224653
757,601 individuals European NR

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM012835 PSS009574|
European Ancestry|
14,004 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Systolic blood pressure β: 2.06 [1.79, 2.32] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012836 PSS009574|
European Ancestry|
14,004 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Diastolic blood pressure β: 1.64 [1.46, 1.81] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012837 PSS009574|
European Ancestry|
14,004 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Pulse pressure β: 0.42 [0.25, 0.58] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012838 PSS009574|
European Ancestry|
14,004 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Hypertension OR: 1.27 [1.23, 1.32] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012839 PSS009575|
African Ancestry|
6,970 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Systolic blood pressure β: 2.38 [1.85, 2.9] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012840 PSS009575|
African Ancestry|
6,970 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Diastolic blood pressure β: 1.39 [1.09, 1.7] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012841 PSS009575|
African Ancestry|
6,970 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Pulse pressure β: 0.99 [0.65, 1.32] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012842 PSS009575|
African Ancestry|
6,970 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Hypertension OR: 1.26 [1.2, 1.33] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012843 PSS009576|
South Asian Ancestry|
8,827 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Systolic blood pressure β: 2.58 [2.13, 3.03] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012844 PSS009576|
South Asian Ancestry|
8,827 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Diastolic blood pressure β: 1.49 [1.25, 1.74] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012845 PSS009576|
South Asian Ancestry|
8,827 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Pulse pressure β: 1.09 [0.8, 1.39] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012846 PSS009576|
South Asian Ancestry|
8,827 individuals
PGP000283 |
Evangelou E et al. Nat Genet (2018)
Reported Trait: Hypertension OR: 1.3 [1.24, 1.36] *Note performance is based on the average between GRS901_SBP and GRS_901_DBP
PPM012863 PSS009584|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Uncontrolled hypertension Odds Ratio (OR, top vs. bottom quintile): 1.7 [1.6, 1.8] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012864 PSS009581|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident major adverse cardiovascular events in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.13 [1.04, 1.23] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012865 PSS009582|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident myocardial infarction in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.08 [0.97, 1.2] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM012866 PSS009583|
European Ancestry|
55,439 individuals
PGP000284 |
Tapela NM et al. Eur J Prev Cardiol (2021)
|Ext.
Reported Trait: Incident stroke in hypertension treatment Hazard Ratio (HR, top vs. bottom quintile): 1.22 [1.06, 1.41] age, sex, socioeconomic characteristics (education, occupation, Townsend deprivation score, and country of residence), metabolic and lifestyle CVD risk factors (smoking status, body mass index, physical activity in METS, and weekly alcohol consumption), family history of CVD (diagnosis at any age), number of antihypertensives and the first four principal components of genetic ancestry, genotyping array and LDL-C value at baseline 881 SNPs remained after QC
PPM013002 PSS009643|
Ancestry Not Reported|
6,335 individuals
PGP000317 |
Parcha V et al. Hypertension (2022)
|Ext.
Reported Trait: Diastolic blood pressure β: 0.65 PGS002258, age, age^2, sex, BMI, randomization arm, history of CVD event, serum creatinine, fasting blood glucose, LDL levels, 10 genetic PCs *NOTE*: PGS is calculated as an average of PGS002257 and PGS002258
PPM013003 PSS009643|
Ancestry Not Reported|
6,335 individuals
PGP000317 |
Parcha V et al. Hypertension (2022)
|Ext.
Reported Trait: Adverse cardiovascular events HR: 1.12 [1.02, 1.23] PGS002258 *NOTE*: PGS is calculated as an average of PGS002257 and PGS002258
PPM013001 PSS009643|
Ancestry Not Reported|
6,335 individuals
PGP000317 |
Parcha V et al. Hypertension (2022)
|Ext.
Reported Trait: Systolic blood pressure β: 1.93 PGS002258, age, age^2, sex, BMI, randomization arm, history of CVD event, serum creatinine, fasting blood glucose, LDL levels, 10 genetic PCs *NOTE*: PGS is calculated as an average of PGS002257 and PGS002258
PPM015498 PSS009963|
European Ancestry|
33,770 individuals
PGP000376 |
Åberg F et al. Sci Rep (2022)
|Ext.
Reported Trait: Liver-related outcome HR: 1.19 [1.01, 1.24] Age, sex, body mass index, waist circumference, weekly alcohol use, fraction of alcohol use as wine, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, diabetes, exercise habits, smoking status (current, former, never smoker) and baseline cardiovascular disease
PPM020416 PSS011352|
Multi-ancestry (including European)|
23,030 individuals
PGP000550 |
Li C et al. J Glob Health (2023)
|Ext.
Reported Trait: Incident diabetic retinopathy Hazard ratio (HR, high vs low PRS tertile): 1.48 [1.21, 1.82] Age, sex, body mass index, ethnicity, Townsend index, smoking status, alcohol consumption, glycosylated haemoglobin, duration of diabetes, anti-hyperglycaemic medication, anti-hypertensive medication, low-density lipoprotein cholesterol
PPM020417 PSS011352|
Multi-ancestry (including European)|
23,030 individuals
PGP000550 |
Li C et al. J Glob Health (2023)
|Ext.
Reported Trait: Incident diabetic kidney disease Hazard ratio (HR, high vs low PRS tertile): 2.8 [1.57, 4.98] Age, sex, body mass index, ethnicity, Townsend index, smoking status, alcohol consumption, glycosylated haemoglobin, duration of diabetes, anti-hyperglycaemic medication, anti-hypertensive medication, estimated glomerular filtration rate
PPM020418 PSS011352|
Multi-ancestry (including European)|
23,030 individuals
PGP000550 |
Li C et al. J Glob Health (2023)
|Ext.
Reported Trait: Incident diabetic neuropathy Hazard ratio (HR, high vs low PRS tertile): 1.04 [0.77, 1.42] Age, sex, body mass index, ethnicity, Townsend index, smoking status, alcohol consumption, glycosylated haemoglobin, duration of diabetes, anti-hyperglycaemic medication, anti-hypertensive medication, estimated glomerular filtration rate
PPM020415 PSS011352|
Multi-ancestry (including European)|
23,030 individuals
PGP000550 |
Li C et al. J Glob Health (2023)
|Ext.
Reported Trait: Incident diabetic microvascular complications Hazard ratio (HR, high vs low PRS tertile): 1.32 [1.11, 1.56] Age, sex, body mass index, ethnicity, Townsend index, smoking status, alcohol consumption, glycosylated haemoglobin, duration of diabetes, anti-hyperglycaemic medication, anti-hypertensive medication, low-density lipoprotein cholesterol and estimated glomerular filtration rate

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS011352 19,883 individuals European UKB Median age of full combined ancestry cohort = 61 years; mean follow-up time of full combined ancestry cohort = 11.95 years
PSS011352 3,147 individuals Not reported UKB Median age of full combined ancestry cohort = 61 years; mean follow-up time of full combined ancestry cohort = 11.95 years
PSS009574 14,004 individuals European Airwave
PSS009575 6,970 individuals African unspecified UKB
PSS009576 8,827 individuals South Asian UKB
PSS009581 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 5,596 cases
  • , 49,843 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009582 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 3,586 cases
  • , 51,853 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009583 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 2,010 cases
  • , 53,429 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009584 The treated hypertension sub-cohort was participants who were presently taking antihypertensive medications (indicated by selecting ‘blood pressure medication’ in response to the question ‘Do you regularly take any of the following medications?’ or reporting an antihypertensive medication in a verbal interview with a trained nurse). The antihypertensive medication classes considered were beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium-channel blocker, alpha blockers, and diuretics. Uncontrolled hypertension was defined as having a mean systolic BP >_140 mmHg or mean diastolic BP >_90 mmHg, among individuals in the treated hypertension sub-cohort. We used prospective follow-up data to assess the composite outcome of incident major adverse cardiovascular events (MACE), which we defined as the first non-fatal stroke (ischaemic or haemorrhagic), non-fatal myocardial infarction, or fatal cardiovascular events, or disease-modifying cardiovascular procedures. We identified MACE components using International Classification of Diseases (ICD-9 and ICD-10) and the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 (OPCS-4) codes from Hospital Episodes Statistics (HES) data, and death registries data. Median = 11.5 years
[
  • 36,114 cases
  • , 19,325 controls
]
,
51.0 % Male samples
Mean = 61.0 years European
(white British)
UKB
PSS009963 Median = 12.9 years 33,770 individuals,
46.5 % Male samples
Mean = 49.6 years European
(Finnish)
Finland FINRISK, Health2000
PSS009643 Corrected for baseline antihypertensive use 6,335 individuals,
62.7 % Male samples
Median = 62.1 years
Sd = [57.8, 67.1] years
Not reported 30.4% non-White individuals ACCORD